🇺🇸 FDA
Pipeline program

Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid Tumors

PM14-A-001-17

Phase 2 other active

Quick answer

Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid Tumors for Advanced Solid Tumors is a Phase 2 program (other) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Advanced Solid Tumors
Phase
Phase 2
Modality
other
Status
active

Clinical trials